Inhibition of neointimal hyperplasia after balloon injury by cis-element 'decoy' of early growth response gene-1 in hypercholesterolemic rabbits

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 126-132

  Ohtani, K ^a   Egashira, K ^a   Usui, M ^a   Ishibashi, M ^a   Hiasa, K I ^a   Zhao, Q ^a   Aoki, M ^b   Kaneda, Y ^b   Morishita, R ^b   Takeshita, A ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Growth factor; Inflammation; Neointimal hyperplasia

Indexed keywords

DNA; DNA BINDING PROTEIN; EARLY GROWTH RESPONSE FACTOR 1; KROX 24 PROTEIN; KROX-24 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PLATELET DERIVED GROWTH FACTOR B; SYNTHETIC DNA; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; FLUORESCENCE ANALYSIS; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; HYPERCHOLESTEROLEMIA; HYPERPLASIA; HYPOTHESIS; IN VIVO STUDY; INTIMA; MALE; METHODOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; RAT; RESTENOSIS; VASCULITIS;

ANGIOPLASTY, BALLOON; ANIMALS; CAROTID ARTERY INJURIES; CAROTID STENOSIS; DNA; DNA-BINDING PROTEINS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE THERAPY; HYPERCHOLESTEROLEMIA; HYPERPLASIA; MODELS, ANIMAL; RABBITS; TRANSCRIPTION FACTORS; TRANSFECTION; TUNICA INTIMA;

ANIMALIA; ORYCTOLAGUS CUNICULUS; SYNTHETIC CONSTRUCT;

EID: 10744232920     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302153     Document Type: Article

References (27)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
3. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-516.
4. Libby P, Ganz P. Restenosis revisited - new targets, new therapies. N Engl J Med 1997; 337: 418-419.
5. Topol EJ, Serruys PW. Frontiers in interventional cardiology. Circulation 1998; 98: 1802-1820.
6. Morice MC et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
7. Sousa JE et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.
8. Khachigian LM, Collins T. Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ Res 1997; 81: 457-461.
9. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 1996; 271: 1427-1431.
10. Khachigian LM. Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. J Clin Invest 2000; 106: 1189-1195.
11. McCaffrey TA et al. High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J Clin Invest 2000; 105: 653-662.
12. Kim S et al. Angiotensin II type 1 receptor blockade inhibits the expression of immediate-early genes and fibronectin in rat injured artery. Circulation 1995; 92: 88-95.
13. Santiago FS et al. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. Nat Med 1999; 5: 1438.
14. Lowe HC et al. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res 2001; 89: 670-677.
15. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023-1028.
16. Mann MJ, Dzau VJ. Therapeutic applications of transcription factor decoy oligonucleotides. J Clin Invest 2000; 106: 1071-1075.
17. Kitamoto S et al. Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation 2000; 102: 806-812.
18. Yu JC et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular proliferation, migration, and suppression of neointima following vascular injury. J Pharmacol Exp Ther 2001; 298: 1172-1178.
19. Deguchi J et al. Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Therapy 1999; 6: 956-965.
20. Yamamoto K et al. Ribozyme oligonucleotides against transforming growth factor-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease. Circulation 2000; 102: 1308-1314.
21. Smith JD et al. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res 1999; 84: 1212-1222.
22. Mori E et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 2002; 105: 2905-2910.
23. Usui M et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 2002; 16: 1838-1840.
24. Egashira K et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90: 1167-1172.
25. Yoshimura S et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element 'decoy' of nuclear factor-kappaB binding site as a novel molecular strategy. Gene Therapy 2001; 8: 1635-1642.
26. Kume M et al. Administration of a decoy against the activator protein-1 binding site suppresses neointimal thickening in rabbit balloon-injured arteries. Circulation 2002; 105: 1226-1232.
27. Usui M et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-310.